Trial data released by Mineralys Therapeutics, Inc. showed that its candidate drug Lorundrostat achieved significant results in reducing the urinary albumin-to-creatinine ratio (UACR).
Show original
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
The improvement of this key biomarker is of significant clinical value for evaluating kidney health, especially in the field of hypertension-related renal injury. The trial results further support the potential value of this drug in targeted therapy and provide a positive signal for subsequent development.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now！
You may also like
Trending news
MoreCrypto prices
More
Bitcoin
BTC
$73,875.63
+0.52%
Ethereum
ETH
$2,025.4
+0.49%
Tether USDt
USDT
$0.9985
-0.00%
BNB
BNB
$719.95
+12.32%
XRP
XRP
$1.35
+2.04%
USDC
USDC
$0.9996
+0.01%
Solana
SOL
$82.91
+1.07%
TRON
TRX
$0.3468
+0.79%
Hyperliquid
HYPE
$67.98
+3.12%
Dogecoin
DOGE
$0.1013
+1.40%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now